The Food and Drug Administration (FDA) is responsible for the safety and effectiveness of drugs sold in the United States. The process to get the FDA’s approval for a pharmaceutical product is usually very long and complicated.
The FDA’s Center for Drug Evaluation and Research (CDER) conducts research to test the drugs’ quality, but the pharmaceutical companies that aim at introducing a new product on the US market are responsible for extensive testing of the drugs to prove they’re safe and effective. The CDER then reviews the data included in the new drug application (NDA). After the development phase, the FDA goes though preclinical and clinical research, review, and post-market safety monitoring.
Experts in this field rarely share their advice on how to deal with the FDA in the most effective way and how to be successful in the pharmaceutical business. “Mastering the art of communication and being proficient in marketing techniques can be helpful,” told us Alessandro Ricci, president of the US branch of the Chinese big pharma company Aurisco. “You have to discover a product’s potential, develop a plan, and clearly describe the assets and advantages a drug can bring to the American market and the world in general,” explained the Italian CEO, product developer and expert of the life-cycle management associated with the supply chain. Having a nice dose of charm, being personable, and able to put people at ease are other important qualities to develop.
Mr. Ricci is responsible for the success of very popular drugs and active substances, such as the extremely popular steroid medicine Fluticasone Propionate, generic of Advair. Sold today under the brand names Flovent and Flonase among others, this product works by decreasing inflammation and is used for the long-term management of asthma, but also to treat hay fever, nasal polyps, and mouth ulcers. With over 24 million prescriptions, Fluticasone was the 23rd most prescribed medication in the United States in 2020. “I make the technical aspects very simple for clients and supervise the document filing for drugs to be successful with the FDA’s approval,” the 43-year-old entrepreneur added.
Mr. Ricci is also the mind behind the development of the Active Pharmaceutical Ingredient (API) Fulvestrant, used in the generic oncologic drug Faslodex and of Abiraterone acetate, a medication used to treat prostate cancer, sold under the brand name Zytiga.
Mr. Ricci’s knowledge of the US marketing and business world has been a crucial asset for many international companies in America. Probably his most important piece of advice is inspired to professional sports and the athlete’s mentality, which he gets from his passion for marathon running: “Be persistent. Just like athletes must train every day in order to be able to finish a marathon, you should fight every day to get to your short-term goals,” he explained. “Working in this field is just like a long-distance race: You need to fight every mile to get to the finish line.”
4 responses to “The Pharmaceutical world and the FDA. Keys for success in the field”
A powerful share, I simply given this onto a colleague who was doing a little bit analysis on this. And he actually bought me breakfast because I discovered it for him.. smile. So let me reword that: Thnx for the treat! But yeah Thnkx for spending the time to debate this, I feel strongly about it and love studying extra on this topic. If potential, as you become expertise, would you mind updating your weblog with more particulars? It’s highly useful for me. Massive thumb up for this weblog put up!
Howdy! I’m at work browsing your blog from my new iphone 4! Just wanted to say I love reading your blog and look forward to all your posts! Keep up the great work!
Thank you for your articles. They are very helpful to me. May I ask you a question?
Hiya, I am really glad I have found this info. Nowadays bloggers publish only about gossips and net and this is actually annoying. A good site with exciting content, that’s what I need. Thanks for keeping this site, I will be visiting it. Do you do newsletters? Can’t find it.